甘精胰岛素300 U/mL在中国2型糖尿病患者中的疗效和安全性:INITIATION研究解读及带来的启示  

Efficacy and safety of insulin glargine 300 U/mL in patients with type 2 diabetes mellitus in China:Interpretation of INITIATION study and its implications

作　　者：纪立农[1] 陈莉明[2] Ji Linong;Chen Liming(Department of Endocrinology,Peking University People′s Hospital,Beijing 100044,China;Department of Endocrinology,National Health Council Key Laboratory of Hormones and Development,Tianjin Key Laboratory of Metabolic Diseases,Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology,Tianjin Medical University,Tianjin 300134,China)

机构地区：[1]北京大学人民医院内分泌科,北京100044 [2]天津医科大学朱宪彝纪念医院内分泌科、天津市内分泌研究所、国家卫生健康委员会激素与发育重点实验室、天津市代谢性疾病重点实验室,天津300134

出　　处：《中华内分泌代谢杂志》2025年第2期89-92,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：基础胰岛素在2型糖尿病患者管理策略中具有重要地位。既往研究证实,甘精胰岛素300 U/mL(insulin glargine 300 U/mL,Gla-300)降糖疗效确切,低血糖风险更低,但缺乏中国真实世界或接近真实临床环境下的疗效和安全性数据。本文述评INITIATION研究并回顾Gla-300在中国基础胰岛素临床实践中的探索过程,提示Gla-300可作为中国胰岛素初治和基础胰岛素转换患者的基础胰岛素优化治疗选择。Basal insulin plays a crucial role in the treatment of patients with type 2 diabetes mellitus(T2DM).Previous clinical trials have demonstrated that insulin glargine 300 U/mL(Gla-300)is effective in improving glycaemic control with a relatively low risk of hypoglycaemia.However,there is limited real-world data on its effectiveness and safety in China.This article reviews the INITIATION study,which evaluated the use of Gla-300 in clinical practice in China,demonstrating that Gla-300 is an effective treatment option for Chinese adults with suboptimally controlled T2DM,whether insulin-naïve or switching from other basal insulins.

关 键 词：糖尿病 2型 基础胰岛素 甘精胰岛素300 U/mL 

分 类 号：R587.1[医药卫生—内分泌]